Enzalutamide Capsules

A drug used to treat prostate cancer that has spread to other parts of the body and is castration sensitive (has responded to treatments that lower testosterone levels) and prostate cancer that is castration resistant (has not responded to treatments that lower testosterone levels). It is also being studied in the treatment of other types of cancer. Enzalutamide binds to proteins called androgen receptors, which are found in some prostate cancer cells. These proteins bind to androgens (male hormones) and may cause cancer cells to grow. Enzalutamide blocks these proteins and may keep cancer cells from growing. It is a type of antiandrogen. Also called Xtandi. US Brand Name(s): Xtandi. FDA Approved Yes.

Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), nonmetastatic castration-resistant prostate cancer, and metastatic castration-sensitive prostate cancer (mCSPC). It is taken by mouth.

Enzalutamide was first described in 2006, and was introduced for the treatment of prostate cancer in 2012. It was the first second-generation NSAA to be introduced. It is on the World Health Organization’s List of Essential Medicines.

Enzalutamide is approved to treat: Prostate cancer. Enzalutamide is also being studied in the treatment of other types of cancer.